RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Blueprint Medicines Stock

Blueprint Medicines ROE 2024

Blueprint Medicines ROE

-3.88

Ticker

BPMC

ISIN

US09627Y1091

WKN

A14SDD

In 2024, Blueprint Medicines's return on equity (ROE) was -3.88, a 258.37% increase from the -1.08 ROE in the previous year.

Blueprint Medicines Aktienanalyse

What does Blueprint Medicines do?

Blueprint Medicines Corp is a biotechnology company that focuses on the discovery, development, and commercialization of drugs for the treatment of genetic diseases. The company was founded in 2008 by a team of experts in the field of molecular biology, biochemistry, and cancer research and is headquartered in Cambridge, Massachusetts, USA. History Blueprint Medicines started as a spin-off from the Broad Institute of MIT and Harvard, a partnership between the Massachusetts Institute of Technology and Harvard University. The founders' goal was to develop a new type of drugs based on the genetic cause of diseases, rather than just treating symptoms. In 2016, the company went public and has since experienced rapid growth. Blueprint Medicines has generated significant revenue through the sale of its products as well as through licensing agreements with other companies. Business model Blueprint Medicines aims to play a leading role in the development of novel drugs based on the identification and treatment of gene mutations. The company utilizes a combination of computer technology, molecular biology, chemistry, and clinical research to specifically target the causes of diseases. Blueprint Medicines has three main areas of focus: 1. Oncology The main focus of Blueprint Medicines is cancer research. The company has several drugs in development that specifically target mutations associated with certain types of cancer. These drugs aim to improve the effectiveness of cancer treatment and enhance patients' quality of life. 2. Blue Flag Technology Blueprint Medicines has developed a proprietary technology called Blue Flag, which allows the company to rapidly and accurately identify and characterize specific mutations in genes. This technology is key to the development of precision medicine approaches tailored to the specific needs of patients. 3. Rare diseases Blueprint Medicines also has a commitment to developing drugs for the treatment of rare diseases. The company collaborates with patients, physicians, and patient organizations to develop drugs that meet the needs of patients with rare diseases. Products Blueprint Medicines has brought several products to market and is working on developing additional products. Here are some of the key products: 1. Ayvakit Ayvakit is a drug for the treatment of gastrointestinal stromal tumors (GIST) associated with a specific genetic mutation. The drug has proven to be highly effective and has been approved by the U.S. Food and Drug Administration (FDA). 2. Gavreto Gavreto is a drug for the treatment of adult patients with a specific genetic mutation associated with non-small cell lung cancer. The drug is being developed in collaboration with pharmaceutical company Roche. 3. Pralsetinib Pralsetinib is a drug for the treatment of patients with a specific gene mutation associated with thyroid cancer. The drug has proven to be highly effective and has been approved by the U.S. FDA. Conclusion Blueprint Medicines Corp is an emerging biotechnology company that focuses on the discovery, development, and commercialization of drugs for the treatment of genetic diseases. The company has established itself as a leader in the field of personalized medicine and has brought several highly effective products to market. Blueprint Medicines continues to work on developing innovative treatment methods for rare diseases and aims to solidify its position as a leading provider of personalized drugs in the global healthcare market. Blueprint Medicines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Blueprint Medicines's Return on Equity (ROE)

Blueprint Medicines's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Blueprint Medicines's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Blueprint Medicines's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Blueprint Medicines’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Blueprint Medicines stock

What is the ROE (Return on Equity) of Blueprint Medicines this year?

The ROE of Blueprint Medicines this year is -3.88 undefined.

How has the Return on Equity (ROE) of Blueprint Medicines developed compared to the previous year?

The ROE of Blueprint Medicines has increased by 258.37% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Blueprint Medicines?

A high ROE indicates that Blueprint Medicines generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Blueprint Medicines?

A low ROE can indicate that Blueprint Medicines is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Blueprint Medicines affect the company?

A change in ROE (Return on Equity) of Blueprint Medicines can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Blueprint Medicines?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Blueprint Medicines?

Some factors that can influence Blueprint Medicines's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Blueprint Medicines pay?

Over the past 12 months, Blueprint Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Blueprint Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Blueprint Medicines?

The current dividend yield of Blueprint Medicines is .

When does Blueprint Medicines pay dividends?

Blueprint Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Blueprint Medicines?

Blueprint Medicines paid dividends every year for the past 0 years.

What is the dividend of Blueprint Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Blueprint Medicines located?

Blueprint Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Blueprint Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Blueprint Medicines from 11/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/26/2024.

When did Blueprint Medicines pay the last dividend?

The last dividend was paid out on 11/26/2024.

What was the dividend of Blueprint Medicines in the year 2023?

In the year 2023, Blueprint Medicines distributed 0 USD as dividends.

In which currency does Blueprint Medicines pay out the dividend?

The dividends of Blueprint Medicines are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Blueprint Medicines stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Blueprint Medicines

Our stock analysis for Blueprint Medicines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Blueprint Medicines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.